Answers are grounded in this paper and cite their sources.
To demonstrate the long-term safety profile of canakinumab over a nine-year period by documenting adverse events in patients with various pediatric rheumatic diseases.
No takes yet. Share an insight, caveat, or question.
Könte et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: